FindTrial
Sign In

A study to assess the effects of Apremilast and Methotrexate in the treatment of patients with psoriasis

An open-labelled randomised comparative evaluation of therapeutic efficacy and safety of Apremilast versus Methotrexate in the treatment of patients with Chronic plaque psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017362
Enrollment
40
Registered
2019-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Apremilast: oral phosphodiestrase-4 inhibitor.Approved by FDA in 2014 and by Central Drugs Standard Control Organization of India in 2017 for plaque psoriasis Control Intervention1: MET

Sponsors

RATHIPRIYADHARSHINI R
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Those With chronic plaque psoriasis involving >10%BSA Those who sign the written consent form prior to participation in the study

Exclusion criteria

Exclusion criteria: pregnancy lactation abnormalities in LFT,RFT,CBC hypertension and diabetes active tuberculosis/ HIV infection Hypersensitivity to the drugs Those on immunosuppresive medications

Design outcomes

Primary

MeasureTime frame
Improvement in PASI[Psoriasis Area and Severity Index] more than 75% from baselineTimepoint: 12 weeks—

Secondary

MeasureTime frame
Improvement in PASI[ PsoriasisArea and Severity Index]Timepoint: 3 weeks,9 weeks—

Countries

India

Contacts

Public ContactRATHIPRIYADHARSHINI R

Chettinad Hospital and Research institute

srinimeghna@gmail.com044-47428101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026